Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib

Bella S. Guerrouahen, Eric Wieder, Elisabeth G. Blanchard, Francis Y. Lee, Richard Aplenc, Seth J. Corey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. Greater use of targeted therapies should involve more quantitative evaluation of the target's dose-inhibition. The Src/Abl kinase inhibitor dasatinib has recently been approved for use in Ph+ leukemias after failure with imatinib. Src family kinases (SFK) also play a critical role in nonhematologic cancers. We have developed a flow cytometric assay to measure SFK autophosphorylation levels in blood mononuclear cells and observed a direct correlation between its inhibition and patient dosage. This method provides a sensitive, quick, and quantitative tool to assess drug efficacy.

Original languageEnglish
Pages (from-to)1132-1135
Number of pages4
JournalPediatric Blood and Cancer
Volume53
Issue number6
DOIs
Publication statusPublished - 8 Dec 2009
Externally publishedYes

Fingerprint

src-Family Kinases
Phosphorylation
Pediatrics
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Blood Cells
Neoplasms
Leukemia
Western Blotting
Imatinib Mesylate
Dasatinib
Therapeutics

Keywords

  • Dasatinib
  • Phase I
  • Src kinases
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. / Guerrouahen, Bella S.; Wieder, Eric; Blanchard, Elisabeth G.; Lee, Francis Y.; Aplenc, Richard; Corey, Seth J.

In: Pediatric Blood and Cancer, Vol. 53, No. 6, 08.12.2009, p. 1132-1135.

Research output: Contribution to journalArticle

Guerrouahen, Bella S. ; Wieder, Eric ; Blanchard, Elisabeth G. ; Lee, Francis Y. ; Aplenc, Richard ; Corey, Seth J. / Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 6. pp. 1132-1135.
@article{5b3c0b54b046436db5111cd342ed93ff,
title = "Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib",
abstract = "Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. Greater use of targeted therapies should involve more quantitative evaluation of the target's dose-inhibition. The Src/Abl kinase inhibitor dasatinib has recently been approved for use in Ph+ leukemias after failure with imatinib. Src family kinases (SFK) also play a critical role in nonhematologic cancers. We have developed a flow cytometric assay to measure SFK autophosphorylation levels in blood mononuclear cells and observed a direct correlation between its inhibition and patient dosage. This method provides a sensitive, quick, and quantitative tool to assess drug efficacy.",
keywords = "Dasatinib, Phase I, Src kinases, Tyrosine kinase inhibitor",
author = "Guerrouahen, {Bella S.} and Eric Wieder and Blanchard, {Elisabeth G.} and Lee, {Francis Y.} and Richard Aplenc and Corey, {Seth J.}",
year = "2009",
month = "12",
day = "8",
doi = "10.1002/pbc.22083",
language = "English",
volume = "53",
pages = "1132--1135",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib

AU - Guerrouahen, Bella S.

AU - Wieder, Eric

AU - Blanchard, Elisabeth G.

AU - Lee, Francis Y.

AU - Aplenc, Richard

AU - Corey, Seth J.

PY - 2009/12/8

Y1 - 2009/12/8

N2 - Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. Greater use of targeted therapies should involve more quantitative evaluation of the target's dose-inhibition. The Src/Abl kinase inhibitor dasatinib has recently been approved for use in Ph+ leukemias after failure with imatinib. Src family kinases (SFK) also play a critical role in nonhematologic cancers. We have developed a flow cytometric assay to measure SFK autophosphorylation levels in blood mononuclear cells and observed a direct correlation between its inhibition and patient dosage. This method provides a sensitive, quick, and quantitative tool to assess drug efficacy.

AB - Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. Greater use of targeted therapies should involve more quantitative evaluation of the target's dose-inhibition. The Src/Abl kinase inhibitor dasatinib has recently been approved for use in Ph+ leukemias after failure with imatinib. Src family kinases (SFK) also play a critical role in nonhematologic cancers. We have developed a flow cytometric assay to measure SFK autophosphorylation levels in blood mononuclear cells and observed a direct correlation between its inhibition and patient dosage. This method provides a sensitive, quick, and quantitative tool to assess drug efficacy.

KW - Dasatinib

KW - Phase I

KW - Src kinases

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=71049119067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049119067&partnerID=8YFLogxK

U2 - 10.1002/pbc.22083

DO - 10.1002/pbc.22083

M3 - Article

C2 - 19484755

AN - SCOPUS:71049119067

VL - 53

SP - 1132

EP - 1135

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -